Welcome to our dedicated page for GeneDx Holdings SEC filings (Ticker: WGS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Interpreting the genomic science, reimbursement discussions, and clinical-trial data buried inside GeneDx’s SEC disclosures can feel like decoding DNA itself. From recognizing revenue tied to whole-genome tests to tracking how rapid NICU sequencing affects margins, the company’s reports are dense with technical language. That’s why investors searching for “GeneDx SEC filings explained simply” start here.
Stock Titan’s platform turns those complexities into clarity. Our AI reads every 10-K annual report, 10-Q quarterly earnings report, and 8-K material events the moment they hit EDGAR, then serves up concise highlights. Need the “GeneDx annual report 10-K simplified” to see year-over-year R&D spending? Done. Curious about clinical-trial milestones disclosed in an 8-K? They’re distilled in seconds—“GeneDx 8-K material events explained.” Real-time alerts flag each “GeneDx Form 4 insider transactions real-time,” letting you monitor “GeneDx executive stock transactions Form 4” without combing filings. Our summaries also connect reimbursement risk factors to revenue trends, so “GeneDx earnings report filing analysis” becomes a quick read instead of a weekend project.
Every filing type unlocks a different lens on this precision-medicine pioneer: the “GeneDx quarterly earnings report 10-Q filing” reveals test-volume growth; the “GeneDx proxy statement executive compensation” shows how leadership is incentivized to expand the rare-disease dataset; “GeneDx insider trading Form 4 transactions” expose buying or selling before pivotal FDA updates. With AI-powered summaries, expert context, and real-time coverage of all forms, understanding GeneDx’s path—from lab bench to bedside—is finally straightforward. Investors use these insights to spot emerging reimbursement trends, evaluate cash burn, and benchmark genomic-data assets—all without wading through hundreds of pages. For anyone “understanding GeneDx SEC documents with AI,” this is the single page to bookmark.
GeneDx Holdings Corp. (WGS) director reports insider share sales. A reporting person serving as a director filed a Form 4 for multiple sales of GeneDx Class A common stock on 11/24/2025. The trades were executed indirectly through investment entities Kariba LLC, Rugu2 LLC and VAAL Investment Partners Q9 LP, where the director has voting and investment power.
The sales occurred in several blocks at weighted average prices ranging from about $157.80 to $162.175 per share, with each block reported separately. After the reported transactions, the filing shows continued indirect beneficial ownership of GeneDx Class A shares by each of the three entities. The director disclaims beneficial ownership of these securities except to the extent of any pecuniary interest.
GeneDx Holdings (WGS) CEO and director reported an RSU settlement and related tax-withholding sales. On 10/29/2025, 3,874 shares of Class A Common Stock were acquired upon RSU vesting at $0 (code M), and 2,154 shares and 4 shares were sold at $136.54 and $136.75, respectively (code S), to cover tax obligations.
After these transactions, the reporting person held 3,436 Class A shares directly. In addition, they held RSUs representing up to 440,665 shares and options for up to 107,610 shares, which vest according to their terms. The RSU award vested 25% on April 29, 2023 and April 29, 2024, and 6.25% on each quarterly anniversary thereafter, with the last tranche scheduled for April 29, 2026.
GeneDx Holdings (WGS) CFO reported routine equity activity. On 10/29/2025, 753 restricted stock units settled into Class A shares at $0, and 388 shares were sold at $136.54 to cover tax withholding tied to the RSU vesting.
After these transactions, the reporting person beneficially owned 3,757 Class A shares. They also held RSUs representing up to 123,880 shares and options to purchase up to 25,906 shares, which vest according to their terms.
The RSU vesting schedule states 25% vested on April 29, 2023 and April 29, 2024, with an additional 6.25% vesting each quarterly anniversary thereafter, with the final tranche scheduled for April 29, 2026.
GeneDx Holdings (WGS) reported Q3 results showing strong top-line growth and improved profitability. Revenue rose to $116.7 million from $76.9 million, lifting gross profit to $84.5 million from $47.8 million. Loss from operations narrowed to $3.3 million from $7.8 million, and net loss was $7.6 million versus $8.3 million a year ago.
For the first nine months, revenue reached $306.6 million versus $209.8 million, with net loss improving to $3.4 million from $57.7 million. Cash and cash equivalents were $95.97 million, and marketable securities were $59.11 million as of September 30, 2025. The company closed the Fabric Genomics acquisition (aggregate purchase price $36.5 million), adding $12.8 million of goodwill and a $6.8 million contingent consideration liability; Fabric contributed $2.0 million of revenue in Q3.
Operating cash flow was $36.4 million year-to-date. Shares outstanding were 28,904,590 as of October 24, 2025; the company issued stock via its ATM in Q3 and year-to-date, raising $11.8 million and $25.6 million, respectively.
GeneDx Holdings Corp. furnished an 8-K announcing it issued a press release and will hold a conference call to discuss financial results for the quarter ended September 30, 2025.
The company attached its Press Release and an Earnings Presentation as Exhibits 99.1 and 99.2. The materials are furnished under Item 2.02 and are not deemed “filed” under Section 18 of the Exchange Act or incorporated by reference, except as specifically stated.
Keith A. Meister, a director and reported 10% owner, amended a Form 4 to correct previously misstated holdings in GeneDx Holdings Corp. (WGS). The amendment clarifies that investment funds advised by Corvex Management LP hold 2,473,781 shares of Class A common stock and that CMLS Holdings LLC holds 333,144 shares, for an aggregate indirect beneficial ownership of 2,806,925 shares. The filing states Mr. Meister may be deemed to indirectly own these shares through his control or board role but disclaims direct beneficial ownership except for any pecuniary interest. The amendment notes the corrected figures reflect a 1-for-33 reverse stock split effective
Katherine Stueland, Chief Executive Officer and a director of GeneDx Holdings Corp. (WGS), reported multiple sales of Class A common stock on 09/30/2025 under a preexisting Rule 10b5-1 trading plan adopted August 16, 2024. The Form 4 shows eight separate sale entries that together reduced her direct beneficial holdings from 13,972 shares to 1,720 shares held directly after the transactions. Reported weighted-average prices for the sales ranged from about $104.98 to $112.04 per share.
The filing discloses that, in addition to the 1,720 directly held shares, Ms. Stueland beneficially owns restricted stock units convertible into up to 444,539 shares and options to purchase up to 107,610 shares that vest according to their terms. The transactions were executed pursuant to the 10b5-1 plan and the Form 4 was signed by an attorney-in-fact on 10/01/2025.
GeneDx Holdings Corp. Chief Financial Officer Kevin Feeley reported multiple transactions in the company’s Class A common stock on 09/30/2025. Mr. Feeley acquired 1,246 shares via exercise of employee stock options at an exercise price of $32.67 and sold a series of shares in multiple transactions under a Rule 10b5-1 trading plan adopted August 21, 2024. The reported sales totaled 7,609 shares across weighted-average prices ranging from about $104.98 to $113.68, leaving the reporting person with 3,392 shares beneficially owned. The filing discloses outstanding RSUs for up to 124,633 shares and options for up to 25,906 shares that vest over time.
Form 144 notice for GeneDx Holdings Corp. (WGS) shows proposed and recent sales of Class A Common Stock by an individual identified in the filing. Two broker-assisted proposed sales are reported for 09/30/2025: 16,425 shares through Morgan Stanley Smith Barney (aggregate market value $1,769,600) and 12,858 shares through Merrill Lynch (aggregate market value $1,390,912). The filing lists the securities as acquired by the seller as restricted stock units on 05/02/2022, 12/09/2022 and 04/26/2023, with acquisition amounts of 3,902, 6,575 and 18,806 shares respectively.
The filing also discloses actual sales by Katherine Stueland during the past three months totaling 29,189 shares for gross proceeds of $3,148,332. The company outstanding share count reported in the notice is 28,726,248, and the proposed combined aggregate market value of the planned sales is $3,160,512.
Thomas Fuchs, a director of GeneDx Holdings Corp. (ticker shown as WGS), was granted 3,438 restricted stock units (RSUs) on 09/17/2025. Each RSU converts into one share of Class A Common Stock for no consideration when settled. The award vests in three equal installments on 09/17/2026, 09/17/2027, and 09/17/2028, subject to the reporting persons continued service. Following the grant, the reporting person beneficially owns 3,438 shares of Class A Common Stock as a direct owner. The Form 4 was signed by an attorney-in-fact on 09/19/2025.
FAQ
What is the current stock price of GeneDx Holdings (WGS)?
What is the market cap of GeneDx Holdings (WGS)?
